GENESIS-PHARMA
GENESIS Pharma, a leading regional biopharma company operating in Europe, and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, announce an exclusive distribution agreement for RIPRETINIB in 14 European markets in Central and Eastern Europe. Under the terms of the agreement, GENESIS Pharma will exclusively commercialize RIPRETINIB for the treatment of fourth-line gastrointestinal stromal tumor (GIST) in: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, and Slovenia.
RIPRETINIB is approved in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Ms. Margarida Duarte, Senior Vice President, Head of International, Deciphera Pharmaceuticals stated: “We are excited to partner with GENESIS Pharma to distribute RIPRETINIB across Central and Eastern Europe, ensuring fourth-line GIST patients in these countries have access to this standard-of-care treatment. Deciphera is committed to commercializing RIPRETINIB globally, and our agreement with GENESIS Pharma builds upon the significant progress we have already made launching the therapy in Europe, positioning us well for continued growth as we work together to improve the lives of GIST patients”.
Mr. Constantinos Evripides, Managing Director of GENESIS Pharma stated: “We are pleased to expand the network of our international partners and honored that Deciphera recognized our expertise and track record in the commercialization of innovative biopharmaceutical products targeting severe and rare diseases. This agreement is an important step forward in expanding our geographical reach and delivering our mission to ensure that such products are made available to patients in the countries we operate. We look forward to joining forces with Deciphera to enable access to this important innovative therapy for eligible patients in Central and Eastern Europe”.
About Gastrointestinal stromal tumor (GIST)
Gastrointestinal stromal tumor (GIST) is a rare neoplasm of the gastrointestinal tract affecting the digestive tract or nearby structures within the abdomen, most often presenting in the stomach or small intestine1. GIST is the most frequent sarcoma of the gastrointestinal tract, with a reported incidence of 10-15 cases per million per year2. The majority of GISTs are driven by two oncogenic protein kinases, KIT and PDGFRA gain-of-function mutations. The most common primary mutations are in KIT kinase, representing approximately 80% of cases, or in PDGFRA kinase, representing approximately 5-10% of cases3. Current therapies are unable to inhibit the full spectrum of primary and secondary mutations, which drives resistance to most tyrosine kinase inhibitors (TKIs) therefore leading to disease progression4. Estimates for 5-year survival rate range from 48% to 90%, depending on the stage of the disease at diagnosis5.
About Deciphera
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, RIPRETINIB is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. RIPRETINIB is approved in Australia, Canada, China, the European Union, Hong Kong, Iceland, Israel, Liechtenstein, Macau, New Zealand, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and X (@Deciphera).
About GENESIS Pharma
GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies. For more information, please visit www.genesispharmagroup.com.
1. Parab TM, DeRogatis MJ, Boaz AM, Grasso SA, Issack PS, Duarte DA, Urayeneza O, Vahdat S, Qiao JH, Hinika GS. Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol. 2019 Feb;10(1):144-154.
2. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 2016 Feb;40:39-46.
3. Lostes-Bardaji MJ, García-Illescas D, Valverde C, Serrano C. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986498.
4. Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP, English JM, Greig MJ, He YA, Jacques SL, Lunney EA, McTigue M, Molina D, Quenzer T, Wells PA, Yu X, Zhang Y, Zou A, Emmett MR, Marshall AG, Zhang HM, Demetri GD. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7.
5. American Cancer Society. (March 1, 2023). Gastrointestinal stromal tumor survival rates. Retrieved December 21, 2023, from https://www.cancer.org/cancer/types/gastrointestinal-stromal-tumor/detection-diagnosis-staging/survival-rates.html.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111379909/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dubai Electricity and Water Authority PJSC Announces Record Annual Revenue of AED 30.98 Billion and an Unprecedented EBITDA of AED 15.70 Billion for the Year 202410.2.2025 16:49:00 CET | Press release
Dubai Electricity and Water Authority PJSC (ISIN: AED001801011) (Symbol: DEWA): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210262973/en/ HE Saeed Mohammed Al Tayer, MD & CEO of DEWA. (Photo: AETOSWire). Full Year 2024* Q4, 2024* AED 30.98 billion AED 15.70 billion AED 7.45 billion AED 3.95 billion +6.18% YoY +6.25% YoY +6.13% YoY +11.11% YoY vs. 2023 Revenue vs. 2023 EBITDA vs. Q4, 2023 Revenue vs. Q4, 2023 EBITDA *Figures are rounded. Ratios are based on actuals. Dubai Electricity and Water Authority PJSC (ISIN: AED001801011) (Symbol: DEWA), the Emirate of Dubai’s exclusive electricity and water services provider, which is listed on the Dubai Financial Market (DFM), today reported its full year 2024 preliminary and unaudited consolidated financial results. DEWA Group recorded consolidated full year revenue of AED 30.98 billion, EBITDA of AED 15.70 billion and net profit after tax of AED 7.24 billion. For Q4, 2024, DE
ShadowDragon Sets a New Standard in Link Analysis, Monitoring, & OSINT by Launching Multilingual Suite10.2.2025 16:21:00 CET | Press release
ShadowDragon Horizon - Empowering Global Investigations in Spanish, French, Italian, German—and More Languages on the Horizon ShadowDragon, a leader in digital investigations and open-source intelligence (OSINT) solutions, today announced the launch of Horizon in multiple languages. Effective immediately, this flagship tool—previously available in English—is now fully localized in Spanish, French, Italian, and German, with additional languages slated for release in the coming months. By expanding language support, ShadowDragon becomes the first in the industry to offer a comprehensive suite of advanced OSINT capabilities designed to serve a wide range of global investigators, law enforcement, and intelligence agencies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250207507777/en/ “ShadowDragon has always led the way in building robust OSINT solutions that keep pace with today’s complex global landscape,” said Daniel Clemen
AV’s JUMP 20 Selected by Danish Defence Acquisition and Logistics Organisation for Tactical UAS Program of Record10.2.2025 15:10:00 CET | Press release
AeroVironment (AV), through its wholly owned subsidiary Arcturus UAV, has been awarded a contract by the Danish Defence Acquisition and Logistics Organisation (DALO) with a contract ceiling value of $181 million to deliver the JUMP® 20 medium uncrewed aircraft system (UAS) to the Danish Armed Forces. This 10-year program of record will equip the Danish Army with JUMP 20 systems to enhance intelligence, surveillance, and reconnaissance (ISR) operations, reinforcing AV’s position as a global leader in advanced autonomous solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210680163/en/ AV to supply its JUMP 20 uncrewed aircraft system to the Danish Armed Forces through new program of record (Photo: AeroVironment) JUMP 20 is a vertical take-off and landing (VTOL), fixed-wing UAS with 13+ hours of endurance and an operational range of 185 km (115 mi). Runway independent, the system is easily storable and transportable,
Tigo Energy Expands Predict+ for Utility Analytics as Platform Approaches 10X Annual Growth10.2.2025 15:00:00 CET | Press release
Predict+ platform surpasses 140,000 meters under management globally, expands advanced feature set, and brings machine learning-powered energy consumption and production prediction to utilities in Europe and North America. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo”), a leading provider of intelligent solar and energy software solutions, today announced a set of powerful enhancements to the Predict+ platform that gives utilities deep insight into grid demand, renewable generation, and energy market dynamics. Designed to enhance the accuracy, scalability, and robustness of energy forecasting with up to 97.5% accuracy through machine learning and artificial intelligence, the platform leverages smart meter consumption data to predict precise grid production and consumption forecasts. Predict+ helps energy providers streamline operations, reduce volatility, and maximize performance. Since the first quarter of 2024, the Predict+ platform has grown from 15,000 to 140,000 meters under management
Veridas Takes the Lead in the Race Against Gen AI Fraud with New Advanced Injection Attack Capability10.2.2025 15:00:00 CET | Press release
Generative AI is fueling a new wave of identity fraud, making digital security more critical than ever. In response, Veridas, a global leader in AI-driven identity verification, has introduced an advanced injection attack detection capability to combat the growing threat of synthetic identities. This new feature strengthens fraud prevention by combining injection detection with liveness verification across face, voice, and document authentication. Injection Attacks: The Hidden Threat in Digital Fraud According to the Veridas Identity Fraud Report 2024, 85% of financial fraud cases now involve synthetic identities. The UK government recently declared deepfakes as the ‘greatest challenge of the online age’, highlighting these growing risks. Fraudsters inject deepfakes and synthetic data directly into identity systems—bypassing device sensors entirely. Traditional fraud detection only analyzes what’s presented (images, videos, or voices), not whether the device is compromised. Veridas has
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom